Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 20;17(4):495-502.
doi: 10.9758/cpn.2019.17.4.495.

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study

Changsu Han  1 , Sheng-Min Wang  2   3 , Won-Myong Bahk  2 , Soo-Jung Lee  2 , Ashwin A Patkar  4 , Prakash S Masand  5 , Chi-Un Pae  2   4   6
Affiliations

The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study

Changsu Han et al. Clin Psychopharmacol Neurosci. .

Abstract

Objective: The present study aimed to observe potential benefit of aripiprazole augmentation in the treatment of major depressive disorder with mixed specifier (MDDM) in naturalistic treatment setting.

Methods: Data were collected from MDDM patients using a retrospective chart review for 8 weeks (week -8 and week 0) in routine practice. All patients were on current antidepressants upon starting of aripiprazole. Patients were treated without restriction of doses of aripiprazole. The primary endpoint was the mean change of Montgomery-Åsberg Depression Rating Scale (MADRS) total scores along with various secondary endpoint measures.

Results: In total 38 patients were analyzed. The changes of MADRS, Clinical Global Impression (CGI)-severity, Young Mania Rating Scale, Sheehan Disability Scale, and CGI-clinical benefit total scores from baseline to the endpoint were -7.1, -0.8, -4.9, -4.1, and -3.6, respectively (all p < 0.0001). At the endpoint, the responder and remitter rates by MADRS score criteria were approximately 32% and 21%, respectively.

Conclusion: The present findings have clearly shown the effectiveness and tolerability of aripiprazole augmentation for MDDM patients in routine practice. The present study warrants subsequent, adequately-powered, well-controlled studies for generalizability near future.

Keywords: Aripiprazole; Depressive disorder; Effectiveness; Mixed specifier; Tolerability..

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

This study was funded by a grant from Korea Otsuka Pharmaceutical. The funding source has not involved in any activities such as study protocol development, study design, data collection, data interpretation, and paper writing.

Figures

Fig. 1
Fig. 1
Changes of outcome measures from baseline in the study. Data represent mean numbers from baseline at each psychometric scale. CGI-CB, Clinical Global Impression-Clinical Benefit; CGI-S, Clinical Global Impression-Severity; MADRS, Montgomery–Åsberg Depression Rating Scale; YMRS, Young Mania Rating Scale; SDS, Sheehan Disability Scale. All p values < 0.001.
Fig. 2
Fig. 2
Responder and remitter rates (%) at the end of treatment in the study. Data represent percentage of subjects as indicated. MADRS, Montgomery–Åsberg Depression Rating Scale; Worsening or no change, no change or increase of MADRS total score; minimal responder, 0% < decrease of MADRS total score < 25%; partial responder, 25% ≤ decrease of MADRS total score < 50%; responder, ≥ 50% decrease of MADRS total score; remitter, 11 ≤ MADRS total score at the end of treatment.
Fig. 3
Fig. 3
Improvement rate by Clinical Global Impression-Improvement (CGI-I) score at the end of treatment. YMRS, Young Mania Rating Scale; CGI-I responder, subject on score 1 or 2 of CGI-I score at the end of treatment; YMRS responder, ≥ 50% decrease of YMRS total score at the end of treatment. Aripiprazole doses: 4.3 ± 3.1 mg/day and 3.9 ± 2.5 mg/day at CGI-I responders and YMRS responders, respectively.
Fig. 4
Fig. 4
Comparison of distribution of Clinical Global Impression-Clinical Benefit (CGI-CB) scores (1 to 10) between baseline and end of treatment. CGI-CB score of 1 indicates the greatest benefit (effectiveness) with least burden (adverse events) from treatment, whereas score of 10 indicates the least benefit with the greatest burden from the treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rush AJ. STAR*D: what have we learned? Am J Psychiatry. 2007;164:201–204. doi: 10.1176/ajp.2007.164.2.201. - DOI - PubMed
    1. Woo YS, Shim IH, Lee SY, Lee DB, Kim MD, Jung YE, et al. Dose trends of aripiprazole from 2004 to 2014 in psychiatric inpatients in Korea. Clin Psychopharmacol Neurosci. 2017;15:177–180. doi: 10.9758/cpn.2017.15.2.177. - DOI - PMC - PubMed
    1. Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, et al. A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial. Clin Psychopharmacol Neurosci. 2018;16:469–480. doi: 10.9758/cpn.2018.16.4.469. - DOI - PMC - PubMed
    1. Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, et al. Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multi-center study. J Psychiatr Res. 2017;91:1–13. doi: 10.1016/j.jpsychires.2017.02.020. - DOI - PubMed
    1. McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsuwaidan MT, et al. The prevalence and illness characteristics of DSM-5-defined “mixed feature specifier” in adults with major depressive disorder and bipolar disorder: results from the International Mood Disorders Collaborative Project. J Affect Disord. 2015;172:259–264. doi: 10.1016/j.jad.2014.09.026. - DOI - PubMed